Pulmicort

ApprovedSmall molecule

UUniversity of California, San Francisco

Pulmicort is one of 91 small molecule programs targeting Sinusitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

Chronic Lung DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

SinusitisPhase 3

Active, not recruiting

Chronic Lung DiseasePhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

Active, not recruiting

AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Pulmicort

UUniversity of California, San Francisco

Approved

3 2

Singulair

AstraZeneca

Preclinical

17 3

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 4

Spiriva

Boehringer Ingelheim

Preclinical

8 5

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Inhaled Corticosteroids

Boehringer Ingelheim

Preclinical

6 8

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

FP/SAL

GSK

Preclinical

2 10

Inhaled Albuterol

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma3 trials

Study of the Mechanisms of Asthma

Completed·UUniversity of California, San Francisco·Phase 1·NCT00595153·127 enrolled

Does Asthma Phenotype Have Impact on Disease Control

Completed·—··NCT01978678·80 enrolled

Effect of Incentive Spirometery on Asthmatic Pregnant Women

Completed·—·N/A·NCT05904002·60 enrolled

Chronic Lung Disease1 trial

Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.

Unknown status·—·Phase 2·NCT01268215·45 enrolled

Sinusitis1 trial

Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis

Completed·UUniversity of Michigan·Phase 3·NCT01197612·23 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

Terminated·WWake Forest University Health Sciences·Phase 4·NCT03219866·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Pulmicort. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pulmicort compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pulmicort. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, San Francisco

Pulmicort

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma3 trials

Chronic Lung Disease1 trial

Sinusitis1 trial

Chronic Obstructive Pulmonary Disease1 trial

References

Drug Info

Quick Facts

Related News